SLNO - NASDAQ

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%

HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.76B

EPS0.4100

P/E Ratio117.86

Earnings Date08/05/2026

slno

Total Other Income Expenses Net

Last Annual Value

5.94M

3-Year CAGR

162%

5-Year CAGR

-4%

10-Year CAGR

14%

Adjust for Inflation

Soleno Therapeutics, Inc. Competitors Analysis of Total Other Income Expenses Net

SLNO · NASDAQ

Company	Total Other Income Expenses Net	CAGR 3Y	CAGR 5Y	CAGR 10Y
Soleno Therapeutics, Inc. NASDAQ:SLNO	5.94M	35.3%	57.2%	14.1%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	-36.00M	N/A	N/A	N/A
Dyne Therapeutics, Inc. NASDAQ:DYN	21.97M	52.3%	97.3%	N/A
Celcuity Inc. NASDAQ:CELC	-4.85M	N/A	N/A	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	22.93M	94.9%	142.9%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	33.70M	31.2%	117.5%	N/A
Apogee Therapeutics, Inc. NASDAQ:APGE	30.03M	49.3%	N/A	N/A
Mirum Pharmaceuticals, Inc. NASDAQ:MIRM	709.00K	N/A	-62.0%	N/A

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $53.01

Related Guides

Blog Categories

Continue your SLNO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.